Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · IEX Real-Time Price · USD
15.27
-0.34 (-2.18%)
May 17, 2024, 4:00 PM EDT - Market closed
Pliant Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Pliant Therapeutics stock have an average target of 46.25, with a low estimate of 36 and a high estimate of 63. The average target predicts an increase of 202.88% from the current stock price of 15.27.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for PLRX stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 4 | 4 | 3 | 4 |
| Buy | 6 | 6 | 5 | 5 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 9 | 9 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $36 | Strong Buy | Reiterates | $36 | +135.76% | May 15, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $45 → $44 | Strong Buy | Maintains | $45 → $44 | +188.15% | May 7, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $54 → $45 | Buy | Maintains | $54 → $45 | +194.70% | May 7, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $47 → $48 | Buy | Reiterates | $47 → $48 | +214.34% | May 7, 2024 |
| Needham | Needham | Strong Buy Reiterates $38 | Strong Buy | Reiterates | $38 | +148.85% | May 7, 2024 |
Financial Forecast
Revenue This Year
671.16K
from 1.58M
Decreased by -57.52%
Revenue Next Year
2.90M
from 671.16K
Increased by 331.94%
EPS This Year
-3.35
from -2.75
EPS Next Year
-3.54
from -3.35
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 4.2M | 21.0M | 21.0M | 199.8M | 733.5M |
| Avg | 671,160 | 2.9M | 4.7M | 50.7M | 192.8M |
| Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 165.8% | 3,028.9% | 624.4% | 4,183.7% | 1,347.5% |
| Avg | -57.5% | 331.9% | 60.9% | 986.5% | 280.5% |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.02 | -2.79 | -2.92 | -0.57 | 4.55 |
| Avg | -3.35 | -3.54 | -3.92 | -3.17 | -1.13 |
| Low | -3.53 | -4.33 | -5.93 | -4.75 | -4.67 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.